Travers Thorp Alberga advised the independent committee of the Board of Tongjitang Chinese Medicines Company (NYSE: TCM) on its privatization by way of merger.  This was the first time that a listed company had used the newly introduced merger provisions to effect a privatization, and so faced particular scrutiny by the SEC.